VK-2019

Phase 2Small molecule

CCullinan Therapeutics Inc.

VK-2019 is one of 73 small molecule programs targeting Nasopharyngeal Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nasopharyngeal CarcinomaActive, not recruiting

Diffuse Large B-Cell LymphomaActive, not recruiting

Nasopharyngeal CancerActive, not recruiting

Diffuse Large B Cell Lymphoma RefractoryRecruiting

Nasopharyngeal CarcinomaPhase 1/Phase 2

Active, not recruiting

Diffuse Large B-Cell LymphomaPhase 1

Active, not recruiting

Nasopharyngeal CancerPhase 2

Active, not recruiting

Diffuse Large B Cell Lymphoma RefractoryPhase 1

Recruiting

Competition

Competitive Landscape

332 competitors in Diffuse Large B-Cell Lymphoma

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

39 2

Gemzar

Johnson & Johnson

Phase 3

19 3

Eloxatin

Teva

Phase 3

17 4

Rayos

RRoxane Laboratories

Phase 3

57 5

Cytosar

Teva

Phase 3

9 6

Adriamycin

GGynecologic Oncology Group

Phase 3

18 7

Trexall

Alnylam Pharmaceuticals

Phase 3

3 8

Afinitor

Novartis

Phase 3

3 9

Kesimpta

Novartis

Phase 3

3 10

Brukinsa

BBeOne Medicines

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Nasopharyngeal Cancer

NCT04925544

Q4 2028

Phase 1Recruiting

Diffuse Large B Cell Lymphoma Refractory

NCT06789159

Clinical

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)

Terminated·CCullinan Therapeutics Inc.·Phase 1/2·NCT03682055·14 enrolled

Diffuse Large B Cell Lymphoma Refractory1 trial

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Recruiting·TThomas Jefferson University·Phase 1·NCT06789159·30 enrolled

Nasopharyngeal Cancer1 trial

Phase 2, Open-label, Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer (NPC) and Other EBV-associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies

Active, not recruiting·SStanford University·Phase 2·NCT04925544·13 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for VK-2019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VK-2019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VK-2019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cullinan Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCullinan Therapeutics Inc.

VK-2019

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q4 2028

Trials by Indication[1]

Nasopharyngeal Carcinoma1 trial

Diffuse Large B Cell Lymphoma Refractory1 trial

Nasopharyngeal Cancer1 trial

References

Drug Info

Quick Facts

Related News